Allogene Therapeutics, Inc.
$2.42
▼
-3.12%
2026-04-21 05:14:00
allogene.com
NMS: ALLO
Explore Allogene Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$582.63 M
Current Price
$2.42
52W High / Low
$4.46 / $0.86
Stock P/E
—
Book Value
$1.27
Dividend Yield
—
ROCE
-53.97%
ROE
-53.42%
Face Value
—
EPS
$-0.87
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
150
Beta
0.54
Debt / Equity
28.46
Current Ratio
7.93
Quick Ratio
7.93
Forward P/E
-3.61
Price / Sales
—
Enterprise Value
$496.12 M
EV / EBITDA
-2.55
EV / Revenue
—
Rating
Buy
Target Price
$7.47
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
| 2. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 3. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 4. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 5. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 6. | Taysha Gene Therapies, Inc. | $6.46 | — | $1.85 B | — | -34.88% | -68.45% | $6.5 / $1.13 | $0.87 |
| 7. | Verrica Pharmaceuticals Inc. | $6.38 | — | $109.6 M | — | -38.9% | -2.4% | $9.82 / $3.28 | $1.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -42.4 M | -44.9 M | -54.44 M | -65.19 M | -60.49 M | — |
| Net Profit | -38.81 M | -41.4 M | -50.94 M | -59.73 M | -59.94 M | — |
| EPS in Rs | -0.16 | -0.17 | -0.21 | -0.25 | -0.25 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.02 M | 0.1 M | 0.16 M |
| Operating Profit | -206.93 M | -257.48 M | -314.49 M | -335.54 M |
| Net Profit | -190.89 M | -257.59 M | -327.26 M | -340.41 M |
| EPS in Rs | -0.78 | -1.06 | -1.34 | -1.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 415.9 M | 548.71 M | 642.84 M | 821.58 M |
| Total Liabilities | 123.36 M | 126.53 M | 130.6 M | 154.7 M |
| Equity | 292.54 M | 422.18 M | 512.23 M | 666.88 M |
| Current Assets | 257.75 M | 303.39 M | 459.12 M | 528.82 M |
| Current Liabilities | 32.51 M | 35.52 M | 37.08 M | 53.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -149.25 M | -200.3 M | -237.73 M | -220.52 M |
| Investing CF | 95.56 M | 75.69 M | 163.29 M | 106.16 M |
| Financing CF | 30.16 M | 116.67 M | 95.69 M | 2.95 M |
| Free CF | -149.63 M | -200.99 M | -239.25 M | -225.71 M |
| Capex | -0.39 M | -0.69 M | -1.52 M | -5.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -76.84% | -39.1% | — | — |
| Earnings Growth % | 21.29% | 3.86% | — | — |
| Profit Margin % | -1170863.64% | -344489.47% | -218214.1% | — |
| Operating Margin % | -1170372.73% | -331044.21% | -215087.18% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1106031.82% | -329543.16% | -205923.72% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.